

INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022



[Registration No.197901003695 (47908-K)] INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

		Individual Quarter		Year to Date	
		Current Year Quarter	Preceding Year Corresponding Quarter	Current Year to	Preceding Year Corresponding Period
	Note	31/03/2022	31/03/2021	31/03/2022	<u>31/03/2021</u>
		RM'000	RM'000	RM'000	RM'000
Revenue		223,298	240,532	223,298	240,532
Cost of sales		(119,289)	(141,363)	(119,289)	(141,363)
Gross profit	_	104,009	99,169	104,009	99,169
Other income		9,047	36,200	9,047	36,200
Selling and marketing expenses		(7,765)	(3,484)	(7,765)	(3,484)
Administrative expenses		(71,857)	(68,148)	(71,857)	(68,148)
Other expenses		(28,970)	(9,743)	(28,970)	(9,743)
Operating (loss)/profit	_	4,464	53,994	4,464	53,994
Finance income		2,316	911	2,316	911
Finance costs		(45,697)	(44,607)	(45,697)	(44,607)
Share of results of joint ventures		1,115	751	1,115	751
Share of results of an associate		2,300	8,293	2,300	8,293
(Loss)/profit before tax		(35,502)	19,342	(35,502)	19,342
Income tax	B5	10,257	(10,967)	10,257	(10,967)
(Loss)/profit for the period		(25,245)	8,375	(25,245)	8,375
Other comprehensive income to be reclassified to profit or loss in subsequent period:					
Foreign currency translation		117	90	117	90
Total comprehensive (loss)/income	_	(25,128)	8,465	(25,128)	8,465
(Loss)/profit attributable to:					
Owners of the parent		(33,394)	2,344	(33,394)	2,344
Holders of perpetual bond		8,626	4,281	8,626	4,281
Non-controlling interests		(477)	1,750	(477)	1,750
	_	(25,245)	8,375	(25,245)	8,375



[Registration No.197901003695 (47908-K)] INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

		Individual Quarter		Year to Date	
			Preceding Year	Preceding Year	
		Current Year	Corresponding	Current Year to	Corresponding
		Quarter	Quarter	Date	Period
	Note	<u>31/03/2022</u>	<u>31/03/2021</u>	31/03/2022	<u>31/03/2021</u>
		RM'000	RM'000	RM'000	RM'000
Total comprehensive (loss)/income attributable to:					
Owners of the parent		(33,277)	2,434	(33,277)	2,434
Holders of perpetual bond		8,626	4,281	8,626	4,281
Non-controlling interests		(477)	1,750	(477)	1,750
	_	(25,128)	8,465	(25,128)	8,465
(Loss)/earnings per share attributable to owners of the parent: (sen per share)					
- Basic	B10	(2.23)	0.16	(2.23)	0.16
- Diluted	B10	(1.38)	0.10	(1.38)	0.10



INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	Note	As At 31/03/2022 RM'000	As At 31/12/2021 RM'000
Assets			
Non-current assets		740 005	750,000
Property, plant and equipment		749,695	756,666
Biological assets Inventories		2,203 7,065,155	1,469 7,071,745
		, ,	•
Investment properties Right-of-use assets		1,509,003 140,489	1,505,658 141,079
Investment in an associate		116,771	141,079
		302,450	300,825
Investments in joint ventures Other investments		302,430 887	300,823 887
Intangible assets		6,309	6,424
Deferred tax assets		223,925	150,665
Trade and other receivables		5,273	5,223
Trade and other receivables		10,122,160	10,055,112
		10,122,100	10,033,112
Current assets			
Biological assets		12	17
Inventories		599,831	566,007
Trade and other receivables		539,313	485,324
Contract cost assets		119,482	120,399
Contract assets		245,485	230,152
Tax recoverable		27,502	15,927
Other investments		157,189	166,700
Cash and bank balances		513,718	638,603
		2,202,532	2,223,129
Asset classified as held for sale		17,500	17,500
	_	2,220,032	2,240,629
Total assets		12,342,192	12,295,741



INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	Note	As At <u>31/03/2022</u> RM'000	As At <u>31/12/2021</u> RM'000
Equity and liabilities			
Equity attributable to owners of the parent		0.420.500	0.046.460
Share capital Irredeemable convertible preference shares		2,132,568 918,193	2,046,168 1,004,593
Treasury shares		(26,263)	(26,103)
Other reserves		1,555,475	1,611,486
Outor 16361V63		4,579,973	4,636,144
Perpetual bond		519,067	527,791
Non-controlling interests		837,539	820,182
Total equity		5,936,579	5,984,117
Non-current liabilities			
Deferred tax liabilities		568,534	507,147
Borrowings	В7	3,330,160	3,371,167
Trade and other payables	D1	513,165	516,818
Irredeemable convertible preference shares		159,429	164,193
Contract liabilities		136,059	133,206
Lease liabilities		8,618	5,609
	_	4,715,965	4,698,140
Current liabilities			
Borrowings	В7	548,814	544,636
Trade and other payables		1,046,800	1,000,254
Irredeemable convertible preference shares		10,009	9,814
Contract liabilities		68,493	47,216
Tax payable		12,320	8,340
Lease liabilities		3,212	3,224
		1,689,648	1,613,484
Total liabilities		6,405,613	6,311,624
Total equity and liabilities	_	12,342,192	12,295,741
Net assets per share (RM)		3.02	3.21

The condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to the interim financial statements.



INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Attributable to owners of the parent <--Non-distributable--> Distributable Irredeemable Foreign Convertible Currency Treasury Share Preference Translation Retained Total Perpetual Non-controlling Total Earnings Shares Capital Shares Reserve Reserves Total Bond Interests Equity RM'000 As at 1 January 2021 2,044,322 1,004,593 (6,882)(109)1,664,257 1,664,148 4,706,181 252,613 800,512 5,759,306 Total comprehensive income 90 2,344 2,434 2,434 1,750 4,184 Distribution for the financial period 4,281 4,281 Distribution paid for the financial period (8,609)(8,609)Transaction with owners: Purchase of treasury shares (4,549)(4,549)(4,549)Total transaction with owners (4,549)(4,549)(4,549)As at 31 March 2021 2,044,322 1,004,593 (11,431) (19)1,666,601 1,666,582 4,704,066 248,285 802,262 5,754,613 As at 1 January 2022 2,046,168 1,004,593 (26,103)156 1,611,330 1,611,486 4,636,144 527,791 820,182 5,984,117 Total comprehensive income/(loss) (33,277)(33,754)117 (33,394)(33,277)(477)Distribution for the financial period 8,626 8,626 Distribution paid for the financial period (17,350)(17,350)Transactions with owners: (22,734)(22,734)17,834 (4,900) Acquisition of non-controlling interests (22,734)Conversion of irredeemable convertible preference shares to ordinary shares 86,400 (86,400)Purchase of treasury shares (160)(160)(160)(5,060) Total transactions with owners 86.400 (86,400) (22,734)(22,734)(22,894)17,834 (160)As at 31 March 2022 2,132,568 918,193 (26,263) 273 1,555,202 1,555,475 4,579,973 519,067 837,539 5,936,579



INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Cash flows from operating activities RM000 RM000 (Loss) (Loss) (profit before tax (35,502) 19,342 Adjustments for: Bepreciation of property, plant and equipment 8,691 7,694 Depreciation of right-of-use assets 1,412 1,023 Amortisation of intangible assets 115 115 Finance income (2,316) (911) Finance costs 45,697 44,607 Share of results of an associate (2,2300) (8,293) Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,848) (12,397) Fair value loss on quoted shares (534) (2,835) Property, plant and equipment written off 3 6 Amortisation of security retainers accumulation fund 3 3 Amortisation of security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital changes (54,000) (158,930) Contract assets (55,000) (58,930)			
Cash flows from operating activities (Loss)/profit before lax (35,502) 19,342 Adjustments for: 1 1 Depreciation of property, plant and equipment 8,691 7,694 Depreciation of right-of-use assets 1,412 1,023 Amortisation of inlangible assets 115 115 Finance income (2,316) (911) Finance costs 45,697 44,607 Share of results of an associate (2,300) (8,293) Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (28,46) (12,937) Fair value loss on quoted shares (28,167) 6,184 Dividend income on quoted shares (534) (2,835) Property, plant and equipment written off 360 - Amortisation of decrered license fees (1,380) (1,139) Amortisation of security retainers accumulation fund (54) (26) Operating profit before working capital changes (54,000) (158,930) Changes in working capital (54,000) (158,930) <tr< th=""><th></th><th>31/03/2022</th><th>31/03/2021</th></tr<>		31/03/2022	31/03/2021
Closs)/profit before tax		RM'000	RM'000
Adjustments for. Bepreciation of property, plant and equipment 8,691 7,694 Depreciation of right-of-use assets 1,412 1,023 Amortisation of intangible assets 115 115 Finance income (2,316) (911) Finance costs 45,697 44,607 Share of results of an associate (2,300) (8,293) Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,848) (12,937) Fair value loss on quoted shares 28,167 6,184 Dividend income on quoted shares (354) (2,835) Property, plant and equipment written off 360 - Amortisation of security retainers accumulation fund 3 3 Amortisation of security retainers accumulation fund 3 46 Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes (8,400) (158,930) Changes in working capital: Trade and other receivables (54,000) (158,930) Contract assets	· · ·		
Depreciation of property, plant and equipment 8,691 7,694 Depreciation of property, plant and equipment 1,412 1,023 Amortisation of intangible assets 1,15 115 Finance income (2,316) (911) Finance costs 45,697 44,607 Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,048) (12,937) Fair value loss on quoted shares 28,167 6,184 Dividend income on quoted shares (334) (2,835) Property, plant and equipment written off 3 62 Right-of-use assets written off 3 62 Right-of-use assets written off 3 6 Amortisation of deferred license fees (1,380) (1,389) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital: (54) (26) Charriage and other receiv	` ',:	(35,502)	19,342
Depreciation of right-of-use assets 1,412 1,023 Amortisation of intangible assets 115 115 Finance income (2,316) (911) Finance costs 45,697 44,607 Share of results of an associate (2,300) (8,293) Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,248) (12,937) Fair value loss on quoted shares 28,167 6,184 Dividend income on quoted shares (8,34) (2,835) Property, plant and equipment written off 3 62 Right-of-use assets written off 360 - Amortisation of security retainers accumulation fund 3 3 Amortisation of security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital. (54) (26) Operating profit before working capital changes (54,000) (158,930) Contract assets (15,333) (13,504) Changes in working capital.	•		
Amortisation of intangible assets 115 115 Finance income (2,316) (911) Finance cots 45,697 44,607 Share of results of an associate (2,300) (8,293) Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,848) (12,937) Fair value loss on quoted shares (34) (2,835) Property, plant and equipment written off 3 60 - Amortisation of security retainers accumulation fund 3 60 - Amortisation of security retainers accumulation fund 3 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital: 18,445 52,138 Changes in working capital: 18,445 52,138 Contract assets (54,000) (158,930) Contract cost assets (54,000) (158,930) Contract liabilities 3,257 2,746 Biological assets (775)			
Finance income (2,316) (911) Finance costs 45,697 44,607 Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,848) (12,937) Fair value loss on quoted shares (28,167) 6,184 Dividend income on quoted shares (534) (2,835) Property, plant and equipment written off 3 62 Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: 3 45 Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract diabilities 3,257 2,746 Biological assets (775) - <td>·</td> <td>•</td> <td></td>	·	•	
Finance costs 45,697 44,607 Share of results of joint ventures (2,300) (8,293) Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,848) (12,937) Fair value loss on quoted shares (534) (2,835) Property, plant and equipment written off 3 62 Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: (54,000) (158,930) Trade and other receivables (54,000) (158,930) Contract assets (54,000) (158,930) Inventories (54,000) (158,930) Contract liabilities 3,257 2,746 Biological assets (775)	· · · · · · · · · · · · · · · · · · ·		
Share of results of an associate (2,300) (6,293) Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,848) (12,937) Fair value loss on quoted shares 28,167 6,184 Dividend income on quoted shares (534) (2,835) Property, plant and equipment written off 3 62 Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital: (54) (26) Trade and other receivables (54,000) (158,930) Contract assets (54,000) (158,930) Contract assets (54,000) (158,930) Contract disabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 <td></td> <td>· · · ·</td> <td>` '</td>		· · · ·	` '
Share of results of joint ventures (1,115) (751) Net gain on disposal of quoted shares (22,848) (12,937) Fair value loss on quoted shares 28,167 6,184 Dividend income on quoted shares (534) (2,835) Property, plant and equipment written off 360 - Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: 18,445 52,138 Changes in working capital changes (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (54,000) (158,930) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets <th< td=""><td></td><td></td><td></td></th<>			
Net gain on disposal of quoted shares (22,848) (12,937) Fair value loss on quoted shares 28,167 6,184 Dividend income on quoted shares (534) (2,835) Property, plant and equipment written off 3 62 Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: (54,000) (158,930) Contract assets (54,000) (158,930) Contract assets (54,000) (158,930) Contract cost assets (54,000) (158,930) Contract liabilities 3,257 2,746 Biological assets (775)			, ,
Fair value loss on quoted shares 28,167 6,184 Dividend income on quoted shares (534) (2,835) Property, plant and equipment written off 360 - Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: (54,000) (158,930) Contract assets (54,000) (158,930) Contract cost assets (15,333) (13,504) Inventories (4,715) (30,034) Contract liabilities 3,257 2,746 Biological assets (775) - Contract liabilities 3,257 2,746 Biological assets (775) - Crotract liabilities 3,257 2,746 <td< td=""><td>•</td><td></td><td>, ,</td></td<>	•		, ,
Dividend income on quoted shares (534) (2,835) Property, plant and equipment written off 3 62 Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Urrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: - - Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract disabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (30,002) (52,957)	· · · ·	• • •	, ,
Property, plant and equipment written off 3 62 Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital: 18,445 52,138 Changes in working capital: (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract diabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (38,635) (45,215) Net taxes paid (30,000) (25,957) Net cash us	·	28,167	
Right-of-use assets written off 360 - Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: - 2,138 Trade and other receivables (54,000) (158,930) Contract assets (54,000) (158,930) Contract cost assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Pinance costs paid (3,8635) (45,215) Net cash used in operating activities (62,545) (92,302) <t< td=""><td>·</td><td>(534)</td><td>(2,835)</td></t<>	·	(534)	(2,835)
Amortisation of deferred license fees (1,380) (1,139) Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital: 18,445 52,138 Changes in working capital: - - Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (7775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (38,635) (45,215) Net taxes paid (32,545) (92,302) Cash flows from investing activities (25,957) Purchase of property, plant and eq		3	62
Amortisation of security retainers accumulation fund 3 3 Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: - Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (21,302) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties	· ·		-
Fair value loss on biological assets 46 - Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (8,25) (25,957) Net cash used in operating activities (62,545) (92,10) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Pur		(1,380)	(1,139)
Unrealised returns on security retainers accumulation fund (54) (26) Operating profit before working capital changes 18,445 52,138 Changes in working capital: Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) (19,003) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (38,635) (45,215) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718)	Amortisation of security retainers accumulation fund	3	3
Operating profit before working capital changes 18,445 52,138 Changes in working capital: 52,138 Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (7775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds	Fair value loss on biological assets	46	-
Changes in working capital: (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495)	Unrealised returns on security retainers accumulation fund	(54)	(26)
Trade and other receivables (54,000) (158,930) Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities Value (62,545) (92,302) Cash flows from investing activities Value (62,288) (92,302) Cash flows from investing activities Value (4,1712) <t< td=""><td>Operating profit before working capital changes</td><td>18,445</td><td>52,138</td></t<>	Operating profit before working capital changes	18,445	52,138
Contract assets (15,333) (13,504) Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) <	Changes in working capital:		
Inventories (4,715) (30,034) Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Trade and other receivables	(54,000)	(158,930)
Contract cost assets (21,602) 36,917 Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities V (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Contract assets	(15,333)	(13,504)
Contract liabilities 3,257 2,746 Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities ** ** Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Inventories	(4,715)	(30,034)
Biological assets (775) - Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Contract cost assets	(21,602)	36,917
Trade and other payables 60,023 89,537 Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Contract liabilities	3,257	2,746
Cash used in operations (14,700) (21,130) Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Biological assets	(775)	-
Finance costs paid (38,635) (45,215) Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities Variable of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Trade and other payables	60,023	89,537
Net taxes paid (9,210) (25,957) Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities Variable of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Cash used in operations	(14,700)	(21,130)
Net cash used in operating activities (62,545) (92,302) Cash flows from investing activities (1,722) (6,288) Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Finance costs paid	(38,635)	(45,215)
Cash flows from investing activitiesPurchase of property, plant and equipment(1,722)(6,288)Purchase of investment properties(3,345)(1,718)Addition of right-of-use assets(1,181)(495)Proceeds from disposal of quoted shares40,04649,497Proceeds from disposal of property, plant and equipment-23Acquisition of quoted shares(35,854)(25,395)Dividend income received5342,835Finance income received2,316911	Net taxes paid	(9,210)	(25,957)
Purchase of property, plant and equipment (1,722) (6,288) Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Net cash used in operating activities	(62,545)	(92,302)
Purchase of investment properties (3,345) (1,718) Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Cash flows from investing activities		
Addition of right-of-use assets (1,181) (495) Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment - 23 Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Purchase of property, plant and equipment	(1,722)	(6,288)
Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment 40,046 49,497 Proceeds from disposal of property, plant and equipment 40,046 49,497 23 Acquisition of quoted shares (35,854) Dividend income received 534 2,835 Finance income received 911	Purchase of investment properties	(3,345)	(1,718)
Proceeds from disposal of property, plant and equipment Acquisition of quoted shares Dividend income received Finance income received 23 (25,395) 2,835 Finance income received 2,316 911	Addition of right-of-use assets		, ,
Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Proceeds from disposal of quoted shares	40,046	49,497
Acquisition of quoted shares (35,854) (25,395) Dividend income received 534 2,835 Finance income received 2,316 911	Proceeds from disposal of property, plant and equipment	-	
Dividend income received 534 2,835 Finance income received 2,316 911		(35,854)	(25,395)
Finance income received 2,316 911	·	• • •	, ,
Net cash generated from investing activities 794 19,370	Finance income received	2,316	
	Net cash generated from investing activities	794	19,370



INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Cash flows from financing activities 403/2022 31/03/2022 RM'000 Payment of borrowing costs (2,282) (10) Drawdown from borrowings 101,637 130,254 Repayment of borrowings (144,570) (46,125) Repayment of principal portion of lease liabilities (956) (705) Placement of debt service reserve, escrow accounts and deposits (51,494) (18,755) Proceeds from issuance of shares to non-controlling interests (4,900) - Purchase of treasury shares (160) (4,549) Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (120,075) 51,501 Net decrease in cash and cash equivalents (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 * Cash and cash equivalents at end of financial period* 254,685 382,751 * Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489)			
Cash flows from financing activities Payment of borrowing costs Payment of borrowings Payment of principal portion of lease liabilities Papament of debt service reserve, escrow accounts and deposits With licensed banks not available for use Proceeds from issuance of shares to non-controlling interests Proceeds from issuance of shares to non-controlling interests Purchase of treasury shares Papament of principal portion of lease liabilities Proceeds from issuance of shares to non-controlling interests Purchase of treasury shares Papament of portion of lease liabilities Proceeds from issuance of shares to non-controlling interests Purchase of treasury shares Papament of position of the po		31/03/2022	31/03/2021
Payment of borrowing costs (2,282) (10) Drawdown from borrowings 101,637 130,254 Repayment of borrowings (144,570) (46,125) Repayment of principal portion of lease liabilities (956) (705) Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use (51,494) (18,755) Proceeds from issuance of shares to non-controlling interests (4,900) - Purchase of treasury shares (160) (4,549) Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (120,075) 51,501 Net decrease in cash and cash equivalents (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period comprise the following: * Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (23,544) (20,007)		RM'000	RM'000
Payment of borrowing costs (2,282) (10) Drawdown from borrowings 101,637 130,254 Repayment of borrowings (144,570) (46,125) Repayment of principal portion of lease liabilities (956) (705) Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use (51,494) (18,755) Proceeds from issuance of shares to non-controlling interests (4,900) - Purchase of treasury shares (160) (4,549) Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (120,075) 51,501 Net decrease in cash and cash equivalents (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period comprise the following: * Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (23,544) (20,007)	Cash flows from financing activities		
Drawdown from borrowings 101,637 130,254 Repayment of borrowings (144,570) (46,125) Repayment of principal portion of lease liabilities (956) (705) Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use (51,494) (18,755) Proceeds from issuance of shares to non-controlling interests (4,900) - Purchase of treasury shares (160) (4,549) Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (120,075) 51,501 Net decrease in cash and cash equivalents (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period* 254,685 382,751 * Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (20,007)	•	(2,282)	(10)
Repayment of borrowings (144,570) (46,125) Repayment of principal portion of lease liabilities (956) (705) Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use (51,494) (18,755) Proceeds from issuance of shares to non-controlling interests (4,900) - Purchase of treasury shares (160) (4,549) Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (120,075) 51,501 Net decrease in cash and cash equivalents (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period* 254,685 382,751 * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (23,544) (20,007)	Drawdown from borrowings	101,637	130,254
Repayment of principal portion of lease liabilities (956) (705) Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use (51,494) (18,755) Proceeds from issuance of shares to non-controlling interests (4,900) - Purchase of treasury shares (160) (4,549) Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (120,075) 51,501 Net decrease in cash and cash equivalents (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period* 254,685 382,751 * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (23,544) (20,007)		(144,570)	(46,125)
with licensed banks not available for use Proceeds from issuance of shares to non-controlling interests Proceeds from issuance of shares to non-controlling interests Purchase of treasury shares (160) Purchase of treasury shares (160) Perpetual bond distribution paid (17,350) Ret cash (used in)/generated from financing activities (120,075) Net decrease in cash and cash equivalents Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts (23,544) (20,007)	Repayment of principal portion of lease liabilities	(956)	(705)
Proceeds from issuance of shares to non-controlling interests Purchase of treasury shares Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (181,826) Effects of foreign exchange rate changes Tash and cash equivalents at beginning of financial period Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Cash and cash equivalents not available for use Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (220,007)	Placement of debt service reserve, escrow accounts and deposits		
Purchase of treasury shares Perpetual bond distribution paid (17,350) Ret cash (used in)/generated from financing activities (120,075) Net decrease in cash and cash equivalents Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts (181,826) (21,431	with licensed banks not available for use	(51,494)	(18,755)
Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (120,075) 51,501 Net decrease in cash and cash equivalents (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period* 254,685 382,751 * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (20,007)	Proceeds from issuance of shares to non-controlling interests	(4,900)	-
Net cash (used in)/generated from financing activities(120,075)51,501Net decrease in cash and cash equivalents(181,826)(21,431)Effects of foreign exchange rate changes11790Cash and cash equivalents at beginning of financial period436,394404,092Cash and cash equivalents at end of financial period*254,685382,751* Cash and cash equivalents at end of financial period comprise the following:Cash and bank balances513,718619,701Less: Cash and cash equivalents not available for use(235,489)(216,943)Less: Bank overdrafts(23,544)(20,007)	Purchase of treasury shares	(160)	(4,549)
Net decrease in cash and cash equivalents Effects of foreign exchange rate changes Cash and cash equivalents at beginning of financial period * Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts (181,826) (21,431) 90 436,394 404,092 254,685 382,751 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) (20,007)	Perpetual bond distribution paid	(17,350)	(8,609)
Effects of foreign exchange rate changes Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts 117 90 436,394 404,092 254,685 382,751 * 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) (20,007)	Net cash (used in)/generated from financing activities	(120,075)	51,501
Effects of foreign exchange rate changes Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts 117 90 436,394 404,092 254,685 382,751 * 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) (20,007)	Net decrease in cash and cash equivalents	(181,826)	(21,431)
Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts 436,394 404,092 382,751 619,701 (216,943) (216,943) (220,007)	·	• •	, ,
* Cash and cash equivalents at end of financial period* * Cash and cash equivalents at end of financial period comprise the following: Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts 254,685 382,751 619,701 (216,943) (216,943) (20,007)		436,394	404,092
Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (23,544) (20,007)			
Less: Cash and cash equivalents not available for use(235,489)(216,943)Less: Bank overdrafts(23,544)(20,007)	* Cash and cash equivalents at end of financial period comprise the following:		
Less: Bank overdrafts (23,544) (20,007)	Cash and bank balances	513,718	619,701
Less: Bank overdrafts (23,544) (20,007)	Less: Cash and cash equivalents not available for use	(235,489)	(216,943)
Total cash and cash equivalents at end of financial period 254,685 382,751	Less: Bank overdrafts	(23,544)	(20,007)
	Total cash and cash equivalents at end of financial period	254,685	382,751